Neuregulin promotes autophagic cell death of prostate cancer cells
Background Prostate cancer is one of the most frequently diagnosed cancers in males. Autocrine/paracrine growth factors for the epidermal growth factor receptor (EGFR) have been identified in prostate tumors suggesting a role for EGFR in the progression of prostate cancer. The androgen‐dependent pro...
Saved in:
Published in: | The Prostate Vol. 55; no. 2; pp. 147 - 157 |
---|---|
Main Authors: | , , , |
Format: | Journal Article |
Language: | English |
Published: |
New York
Wiley Subscription Services, Inc., A Wiley Company
01-05-2003
Wiley-Liss |
Subjects: | |
Online Access: | Get full text |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Summary: | Background
Prostate cancer is one of the most frequently diagnosed cancers in males. Autocrine/paracrine growth factors for the epidermal growth factor receptor (EGFR) have been identified in prostate tumors suggesting a role for EGFR in the progression of prostate cancer. The androgen‐dependent prostate cancer cell line, LNCaP, expresses the EGFR as well as two additional members of the family; ErbB‐2 and ErbB‐3, which can be activated by neuregulin (NRG) isoforms. The effect of ErbB ligands on the viability of LNCaP cells was studied.
Methods
In the present study, we examined the effect of NRG on LNCaP cell growth and survival in the absence of androgen mimetic by the MTT assay, FACS analysis, nuclei staining, and Western blotting.
Results
Our results demonstrate that NRG activates ErbB‐2/ErbB‐3 heterodimers and induces cell death of LNCaP cells. By contrast, EGF activates ErbB‐1/ErbB‐1 or ErbB‐1/ErbB‐2 dimers and induces cell growth and survival. Interestingly, LNCaP cells treated with PI3K inhibitor underwent cell death but cells treated with both NRG and PI3K inhibitor survived as the control cells, indicating that the PI3K pathway may mediate NRG‐induced cell death. NRG‐induced cell death was not inhibited by the broad‐spectrum caspases inhibitor, benzyloxycarbonyl‐Val‐Ala‐Asp‐fluoromethylketone (Z‐VAD‐FMK). However, NRG‐induced cell death was inhibited by type II cell death inhibitor, 3‐methyladenine.
Conclusions
These results suggest that NRG induces type II cell death of LNCaP cells through PI3K‐dependent pathway. Prostate 55: 147–157, 2003. © 2003 Wiley‐Liss, Inc. |
---|---|
Bibliography: | Israel Cancer Association - No. 20010055-B Chief Scientist's Office of the Israel Ministry of Health - No. 5277 istex:A97B616621914B4F7B05FEBBFA3F2B51DE0BFAB4 Ela Kodesz Institute, Israel ArticleID:PROS10200 ark:/67375/WNG-QRZLJ7S9-M ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 |
ISSN: | 0270-4137 1097-0045 |
DOI: | 10.1002/pros.10200 |